SAFE or Priced Round? What Changes at Your First Raise

A SAFE and a priced round both turn investor cash into equity, but they differ on one question: whether you set a valuation now. A SAFE (simple agreement for future equity) is a contract that converts into shares at a later priced round, usually at a valuation cap or a discount, so you can raise without agreeing on what the company is worth today. SAFE holders are not yet stockholders and usually get no vote and no board seat. A priced round sells preferred stock at an agreed valuation, and with it come the terms that shape the company for years: who sits on the board, what investors can veto, and how they are protected if a later round comes in lower. SAFEs suit early money from angels and smaller funds. A priced round tends to follow once a lead investor is ready to underwrite a valuation, which usually means the company has hit milestones that justify one.
This guide covers what each instrument actually commits you to, how SAFEs convert and stack up, why the first priced round sets terms that carry into every round after it, and how to reason about how much to raise.
In this guide
- What a SAFE is, and what it is not
- What a priced round adds
- SAFE and priced round, side by side
- How SAFEs convert, and why they stack
- The first priced round sets the table
- How much to raise
- When you have one term sheet
- Where Founders Form fits
What a SAFE is, and what it is not
A SAFE is an investment contract, not stock. The investor pays now, and the company promises shares later, when a defined event happens. The usual trigger is the next priced equity round. If the company is sold first, the SAFE typically pays out either the original investment or the amount the converted shares would have been worth, whichever is greater. If the company shuts down, SAFE holders generally rank behind creditors but ahead of common stockholders for whatever is left.
The point of a SAFE is to defer the valuation question. As Omed Sharifi put it on the Founders Form Podcast, a SAFE is typical at pre-seed "because you don't have to set a valuation at that stage in time right now." Two terms do most of the work instead:
- Valuation cap. The maximum valuation at which the SAFE converts. If the priced round comes in above the cap, the SAFE holder converts as if the price were set at the cap, which rewards them for investing early.
- Discount. A percentage off the price new investors pay in the priced round. Some SAFEs carry a cap, some a discount, some both, in which case the investor gets whichever is better for them.
The standard form most U.S. startups use is Y Combinator's post-money SAFE, published in 2018. Its key feature is that the cap is measured after all SAFE money is counted, so each investor knows exactly what percentage of the company they are buying before the priced round. That clarity for the investor has a cost for founders, covered below.
What a SAFE usually does not include: a board seat, voting rights, protective provisions, or a liquidation preference of its own until it converts. Side letters can add things, most often pro rata rights (the right to invest in the next round) or a "most favored nation" clause that upgrades the SAFE if later SAFEs get better terms. Read those as carefully as the SAFE itself.
What a priced round adds
In a priced round, the company and its lead investor agree on a valuation, and investors buy newly issued preferred stock at a set price per share. In Omed's words, it happens when an investor is "committing a huge amount of money to you and underwriting a deal. They and you are agreeing that your company is fairly firmly valued at this amount of dollars."
The valuation is the headline, but the documents carry the weight. Most U.S. venture rounds are papered on documents based on the NVCA model forms: an amended certificate of incorporation, a stock purchase agreement, an investors' rights agreement, a voting agreement, and a right of first refusal and co-sale agreement. Between them, they settle questions a SAFE never asks:
- Board composition. Who names each director. This is often the round where an investor director first joins. Our guide to startup board governance from seed to Series C walks through how the board typically changes round by round.
- Protective provisions. The list of decisions the preferred stockholders can veto, such as selling the company, issuing a new senior class of stock, or changing the charter.
- Liquidation preference. How much investors get back before common stockholders in a sale. A 1x non-participating preference is common in early rounds, but it is negotiated.
- Anti-dilution protection. How the investors' conversion price adjusts if a later round is priced lower, usually on a broad-based weighted average formula.
- Information and pro rata rights. What financial reporting investors receive, and their right to buy into future rounds.
All of the outstanding SAFEs typically convert into preferred stock at the same closing. A priced round therefore costs more in legal time and takes longer to close than a SAFE, because there is more to negotiate and every term has a second-round consequence.
SAFE and priced round, side by side
| SAFE | Priced round | |
|---|---|---|
| What the investor gets | A contract for future shares | Preferred stock, issued at closing |
| Valuation | Deferred; a cap and/or discount sets the conversion terms | Agreed now, as a price per share |
| Board seat | Usually none | Often one for the lead investor |
| Voting and vetoes | Usually none until conversion | Voting rights plus protective provisions |
| Documents | One short standard form, plus any side letters | A full set, usually based on the NVCA models |
| Who leads | No lead required; investors can sign one at a time | A lead investor who sets the price and terms |
| Typical stage | Pre-seed, and many seed rounds | Seed or Series A onward |
How SAFEs convert, and why they stack
Under a post-money SAFE, the investor's ownership at conversion is the investment divided by the post-money valuation cap. A $500,000 SAFE with a $10 million post-money cap converts into 5% of the company, measured just before the priced round's new money comes in.
That arithmetic is simple for one SAFE and easy to lose track of across several. Because each post-money SAFE locks in its own percentage, raising more SAFEs does not dilute the earlier SAFE holders. It dilutes the founders and other common holders. Raise $500,000 on a $10 million cap, then $1 million on a $12 million cap, and roughly 13% of the company is already spoken for before the lead investor in the priced round buys anything. The lead then takes their own percentage on top, and most rounds also ask the company to top up its option pool from the pre-money side.
None of this is a reason to avoid SAFEs. It is a reason to keep a running pro forma cap table that models every SAFE converting at once, and to look at it before signing the next one.
The first priced round sets the table
The SAFE stage is light on terms by design. The first priced round is where the terms arrive, and they tend to stay. Omed describes it this way:
"What you're doing at your first priced round is you're setting the table. And when you set the table, the table is going to remain there. There might be some new plates or dishes added in the future, but this is your base."

Later investors usually start from the terms already in the charter and the investor agreements. Unusual terms agreed early (a heavy liquidation preference, a broad veto list, a board structure that hands away control) are hard to unwind without leverage, and leverage usually comes from growth the company may not have yet.
Founder vesting is the clearest example. A common structure is four years with a one-year cliff: nothing vests for the first twelve months, 25% vests at the one-year mark, and the rest vests monthly over the following three years. Some founders skip vesting at incorporation to protect their position if they leave or are pushed out. That can survive an early round. But a new lead investor at Series A, looking at a company whose value now depends on its founders staying, will often ask for founders to re-vest, which can restart the clock on equity the founders thought they had already earned. Putting a reasonable vesting schedule in place early, with credit for time already served, is usually a better starting point than negotiating it from scratch later.
As Omed put it, "every decision that you make at seed is interconnected. It's not just one thing in a silo."

How much to raise
The useful question is not how much investors will give you. It is how much you need to reach the milestone that justifies the next round, plus a buffer. At pre-seed, that milestone might be a working product or a first enterprise customer. At seed, it is often a user count or revenue figure. For a biotech company, it might be the data from a specific study phase.
Omed's rule of thumb is to raise enough runway to reach that next milestone in roughly two to two and a half years, while noting the timeline is compressing for companies built around AI.
Then the amount has to square with the valuation. The percentage you sell equals the amount raised divided by the post-money valuation. Raising $2 million while selling 20% implies a $10 million post-money valuation. Raise more at the same percentage and the implied valuation goes up with it.
A higher valuation sounds better, and sometimes it is. But every round needs the company to have grown into the last one. If the next round is priced below the previous one, that is a down round: anti-dilution protections adjust in the investors' favor, common holders take the extra dilution, and the story the company tells new investors gets harder. "You want to grow into your valuation," Omed says. "This is a very long game."

So the question for the first raise is how much you actually need, and how much of the company you are prepared to sell across every round you expect to raise, not only this one. If you are still working out whether venture funding is the right path at all, start with whether your startup is venture-backable.
When you have one term sheet
A single term sheet is not a reason to refuse it. Two questions are worth answering first.
First, are the terms standard? A plain term sheet close to market norms is often worth taking even without a competing offer. Whether a term is standard is hard to judge from the inside on a first round, and it is the part of the process where an experienced lawyer earns the fee. Our guide on how to choose a lawyer for your seed or Series A round covers what to look for.
Second, are you ready for how the company changes once outside investors hold preferred stock? There may be an investor on the board, stockholders with a say in major decisions, and reporting obligations that did not exist before. That change comes with venture funding eventually. The question is whether now is the right time for it, and whether the money gives you enough runway to grow into the valuation you are agreeing to.
Early advisors and mentors can be useful here too, as long as their role is clear. Our article on finding a startup advisor before you raise covers what a good one does.
Where Founders Form fits
Founders Form is a law firm in Palo Alto for venture-backable startups. It handles fundraising from SAFEs through Series C, including the board, vesting and investor terms negotiated in each round, and works with funded companies as outside general counsel afterward. Omed Sharifi, who leads the firm, practiced at Cooley, Fenwick & West and Morrison & Foerster before founding it, and works directly with founders rather than through a rotating team.
Legal work is billed hourly, and fractional general counsel is available at a fixed monthly fee scoped to each company. The fundraising work is described on the startups raising capital page, and ongoing support after the round on the outside general counsel page.
This article is general information about startup financing, not legal advice about your company's situation. SAFE and financing terms vary from deal to deal, and speaking with a lawyer about your specific documents is the only way to know what yours say.